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Abstract: Glaucoma is a collection of diseases characterized by multifactorial progressive 
changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocu-
lar pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic 
nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, 
progresses to combination therapy with agents from up to 4 different classes of IOP-lowering 
medications, and then proceeds to laser or incisional surgical modalities for refractory cases. 
The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 
2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the 
treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic 
blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide–timolol 
has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination 
dorzolamide–timolol is convenient for patients, reduces their dosing regimen with the goal of 
increasing their compliance, reduces the effects of “washout” when instilling multiple drops, 
and reduces the preservative burden by reducing the number of drops administered per day.
Keywords: dorzolamide, timolol, glaucoma, ocular hypertension, elevated IOP, fixed 
  combination therapy
Introduction to glaucoma, ocular hypertension 
management, and patient compliance
Background
Glaucoma is the leading cause of irreversible blindness throughout the world, accounting 
for blindness in 5.1 million persons according to the World Health Organization 1995 
statistics. In the United States (US), glaucoma is the second leading cause of blindness 
and most frequent cause of blindness among blacks.1 The term glaucoma refers to a col-
lection of diseases with diverse clinical and histopathologic   manifestations characterized 
by progressive, distinctive changes in the visual field and the optic nerve.1,2
Aqueous humor is produced by the ciliary body and drains out of the eye primarily 
through the trabecular meshwork within the anterior chamber angle. In open angle 
glaucoma (OAG), elevation in IOP results from an increased resistance to aqueous 
outflow at the level of the trabecular meshwork.2 Elevated intraocular pressure (IOP), 
or ocular hypertension (OH), is an important risk factor for the development of 
  glaucoma, although some patients may develop characteristic optic nerve and visual 
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epidemiology
The prevalence of OAG in persons 40 years and older is 
estimated to be around 1% to 5% of the population in the 
US,3 1% to 3% in Europe,4,5 1% to .8% in Africa,4,5 1% to 
4% in Asia,4,5 and 2% to 3% in Australia.4,5 The incidence 
of “definite” OAG is about 0.1% to 0.2% per year in mainly 
European populations, and an even higher incidence of 
0.5% per year has been reported for black participants in 
one study, which rises to 1.0% per year if “probable” cases 
of OAG are included.3
Medical treatment of glaucoma
Lowering the IOP is recognized to retard or prevent addi-
tional damage to the optic nerve. Treatment for glaucoma 
is generally administered with topical eye drops. The goal 
of therapy is to lower the IOP below the threshold at which 
damage to the optic nerve is incited. In addition to being 
efficacious, the treatment must be safe and well tolerated 
by the individual patient. To minimize the risk of local 
and systemic side effects, clinicians typically employ 
the fewest medications necessary to achieve the desired 
therapeutic effect.
Since the 1970s, topical beta blocker medications such 
as timolol maleate 0.5% (Timoptic®; Merck & Co., Inc., 
Whitehouse Station, NJ, USA) dosed once or twice daily 
have been utilized as first-line therapy choices in the treat-
ment of   glaucoma.6 Prior to that, cholinergic agonists (topical 
pilocarpine, carbachol, and phospholine iodide), nonspecific 
adrenergic agonists (topical epinephrine   [Epifrin®; Allergan, 
Inc., Irvine, CA, USA] and dipivefrin hydrochloride[Propine®; 
  Allergan, Inc.]), and oral carbonic anhydrase inhibitors 
(acetazolamide [Diamox®; Lederle, Pearl River, NY, USA] 
and methazolamide [Neptazane®; Lederle, Pearl River, NY, 
USA]) were the mainstays of glaucoma therapy; however, 
some of these (eg, epinephrine and dipivefrin) are no longer 
routinely used due to their side effect profiles.6 Over the 
past 20 years, the armamentarium of topical medications to 
treat glaucoma expanded to include selective α2-adrenergic 
agonists   (apraclonidine 0.5% [Iopidine®; Alcon Laboratories, 
Inc., Fort Worth, TX, USA] and brimonidine tartrate (in con-
centrations from 0.1% to 0.2%) [Alphagan®/Alphagan P®; 
Allergan, Inc.]), topical carbonic anhydrase inhibitors (dor-
zolamide hydrochloride 2% [Trusopt®; Merck & Co., Inc.] 
and brinzolamide 1% [Azopt®; Alcon Laboratories, Inc.]), 
and prostaglandin F2α analogs (latanoprost 0.005% [Xalatan®, 
Pfizer, Inc. New York, NY, USA], travoprost 0.004% [Trava-
tan®/Travatan Z®; Alcon Laboratories, Inc.], and bimatoprost 
0.03% [Lumigan®; Allergan, Inc.]).
Patients with OAG are usually treated initially with 
monotherapy with 1 drug class (eg, timolol maleate 0.5%) 
and other classes of medications are added as necessary 
to lower the IOP into the desired target range. Many of 
the patients who are using IOP-lowering treatments require 
more than 1 class of medication to reduce their IOP to the 
desired levels. In the treatment arm of the Ocular Hyperten-
sion   Treatment Study, medications were added until the 
goal of IOP , 24 mmHg and at least 20% reduction in IOP 
from baseline was maintained. At 5 years, 2 or more topical 
medications were required for 39.7% of the patients and 3 or 
more medications were prescribed for 9.3% of the patients in 
the medication treatment arm of the study.7 In a large observa-
tional study where 1990 patients with primary OAG (POAG) 
or OH were enrolled in 9 countries, less than half (48%) of the 
patients remained on beta blocker monotherapy after 2 years, 
56% of the patients who required additional therapies being 
switched to a topical fixed combination treatment.8
Patient compliance
Patient compliance includes adherence (how well the patient 
follows the physician’s prescribed orders) and persistence 
(how long the patient remains on therapy). Patient noncompli-
ance with medications is a concern regardless of the medica-
tion that is prescribed. Patients’ adherence to the prescribed 
daily regimen decreases with increased dosing frequency.9 
Reviews of studies that analyze compliance have shown that 
less complex dosing regimens resulted in better adherence to 
the plan. Claxton et al reviewed a total of 76 studies where 
compliance was measured with electronic monitoring devices 
rather than less accurate methods such as patient self-report, 
blood-level monitoring, prescription refills, or pill count 
data. Mean dose-taking compliance across these 76 studies 
was 79% for once-daily dosing, 69% for twice-daily dosing, 
65% for 3-times-daily dosing, and 51% for   4-times-daily 
dosing.10 Noncompliance with recommended medical therapy 
is a major problem in the treatment of a chronic and typically 
asymptomatic disease such as glaucoma because the treatment 
lacks positive feedback (such as symptomatic relief) and may 
cause local ocular and/or systemic side effects.11 A   historical 
literature review by Greenberg related the frequency of dosing 
and other influences with patient compliance in medication 
taking. Once-a-day and twice-a-day regimens were associated 
with significantly better   compliance (73% ± 6% [range 42% 
to 93%] and 70% ± 5% [range 50% to 94%], respectively) 
than were 3-times-daily (52% ± 7% [range 18% to 89%]) 
and 4-times-daily (42% ± 5% [range 11% to 66%]) dosing 
regimens.12Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Combination therapy
Fixed combination formulations may improve compliance by 
reducing the number of daily eye drops, thereby simplifying 
the dosing regimen.11,13–15 Pilocarpine and epinephrine were 
combined to treat glaucoma as early as the 1960s. After 
timolol maleate 0.5% became available in 1978, fixed com-
binations of timolol–pilocarpine and timolol–epinephrine 
followed. Dorzolamide hydrochloride 2% was approved by 
the US Food and Drug Administration (FDA) in 1995 for 
3-times-daily dosing. Dorzolamide hydrochloride 2% and 
timolol maleate 0.5% were formulated as a fixed combination 
product (Cosopt®; Merck and Co., Inc.) and approved by the 
FDA in 1998 to provide a more convenient dosing regimen for 
patients requiring multiple medications.9 The IOP-lowering 
effect of the fixed combination dorzolamide–timolol was 
greater than that of either of its components administered as 
monotherapy. This combination is generally well tolerated 
and provides a convenient alternative to concomitant therapy 
with its individual components.9 Another inherent benefit of 
fixed combination therapy versus concomitant therapy with 
multiple drugs is that fixed combination therapies decrease 
the preservative load to which the patients’ eyes are exposed. 
They also eliminate the effects of having the first instilled 
drug being diluted or “washed out” by the second instilled 
eye drop. The dorzolamide–timolol fixed combination was 
released to market as a generic in October 2008.16
A fixed combination of timolol maleate 0.5% and bri-
monidine tartrate 0.2% (Combigan®; Allergan, Inc.) has also 
been available in the US since 2007. Fixed combinations of 
timolol maleate 0.5% with latanoprost 0.005% (Xalacom®; 
Pfizer, Inc.), travoprost 0.004% (Extravan® or Duotrav®; 
Alcon Laboratories, Inc.), bimatoprost 0.03% (Ganfort®; 
Allergan, Inc.), and brinzolamide 1% (Azarga®; Alcon 
Laboratories, Inc.) are available outside the US. A fixed 
triple combination of timolol maleate 0.5%, dorzolamide 
hydrochloride 2%, and brimonidine tartrate 0.2% (Krytanek 
Ofteno®; Laboratorios Sophia, Mexico) has recently become 
available as well.17
Pharmacology
Pharmacodynamics
Although both dorzolamide hydrochloride 2% and timolol 
maleate 0.5% decrease elevated IOP by decreasing   aqueous 
humor production, they each appear to have a different 
mechanism of action at the molecular level and they appear 
to have an additive or synergistic effect when administered 
together either concomitantly or as part of a fixed combination 
product.18 Carbonic anhydrase inhibitors decrease   aqueous 
secretion due to lack of bicarbonate ions.19 Dorzolamide is 
a carbonic anhydrase inhibitor that is highly selective for 
the carbonic anhydrase isoenzyme II (CA-II) and lowers 
IOP by inhibiting CA-II in the ocular ciliary process, thus 
decreasing aqueous humor production while also improv-
ing hemodynamic ocular blood flow. Dorzolamide also has 
the systemic effect of inhibiting the CA-II isoenzyme in 
erythrocytes.18 When administered topically in the eye, beta 
blockers reduce IOP by a mechanism that involves reduced 
production of aqueous humor by the ciliary body, which is 
physiologically activated by cAMP.19 Timolol is a nonselec-
tive beta-adrenoreceptor antagonist (beta-1 and beta-2), with 
no local anesthetic, membrane stabilizing, or sympathomi-
metic properties, which lowers IOP by inhibiting aqueous 
humor production with no hemodynamic effects on ocular 
blood flow. Timolol has the systemic effect of reducing heart 
rate and blood pressure. While the maximal daily dose that 
is usually applied locally to the eye is small relative to the 
usual daily doses used for systemic administration of beta 
blockers to treat conditions such as hypertension, enough of 
the timolol may be absorbed from the eye as to cause seri-
ous adverse effects on the heart and airways of susceptible 
individuals.18,19
Pharmacokinetics
No specific information on the pharmacokinetic proper-
ties of the fixed combination of dorzolamide–timolol has 
been published, and thus the pharmacokinetics of the 
individual components are discussed herein. After topical 
ocular administration, dorzolamide enters the systemic 
circulation via drainage through the nasolacrimal duct and 
absorption from the nasopharyngeal mucosa. Systemically 
absorbed dorzolamide binds mainly to CA-II in the red 
blood cells with plasma protein binding of the drug at 33%. 
Dorzolamide is metabolized slowly by the cytochrome P450 
(CYP) 2B1/2, CYP2E1, and CYP3A2 isoenzymes in the 
liver to a single N-desethyldorzolamide metabolite, which 
also accumulates in erythrocytes where it binds primarily to 
carbonic anhydrase isoenzyme I (CA-I). Dorzolamide and 
N-desethyldorzolamide are excreted predominantly via the 
renal route, accordingly use of the fixed combination is not 
recommended (in the US) or is contraindicated (in Europe) 
in patients with severe renal impairment.
Timolol is absorbed systemically in the same way as 
is dorzolamide. Instillation of 2 drops of timolol maleate 
0.5% into the eyes of 20 patients undergoing cataract 
surgery produced timolol concentrations ranging from 
150 ng/100 mg of aspirated aqueous humor in the first 1 to Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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2 hours to 10 ng/100 mg aspirated aqueous humor towards 
the end of 7 hours. Between 5% and 46% of the calculated 
absorbed dose of timolol maleate 0.5% was excreted renally 
over 24 hours following ocular administration of the drug as 
2 drops in each eye.18
Available formulations of fixed 
combination dorzolamide–timolol
In addition to the brand name dorzolamide–timolol fixed com-
bination product (Cosopt®), as the time of writing, at least 4 
pharmaceutical manufacturers are currently producing generic 
versions of the fixed combination   dorzolamide–timolol.20 
A review of the key characteristics of the available formula-
tions of fixed combination dorzolamide–timolol as docu-
mented in the respective products’ package inserts (labeling), 
including the concentration of the 2 active ingredients, the 
choice of preservative used and the concentration thereof in 
the formulation, as well as a review of the inactive ingredi-
ents, revealed that there are no significant differences in these 
parameters among the available formulations. Anecdotally, 
patients have reported differences in side effects among the 
various generic products, but no controlled trials have been 
published that document these observations.
Preservative-free fixed combination  
of dorzolamide–timolol
Preservative-free Cosopt® has been developed as an alterna-
tive for those patients allergic or sensitive to the commonly 
used preservative benzalkonium chloride (BAK). One study 
has shown that this formulation lowers IOP by 38% from 
baseline at 8 weeks without significantly increasing ocular 
discomfort (as measured by the Glaucoma Symptom Scale 
[GSS-SYMP-6]).21 A second report demonstrated that both 
the preservative-free and preservative-containing formu-
lations of dorzolamide–timolol fixed combination were 
equivalent in efficacy in IOP changes at peak and trough. 
Additionally, this study reported similar tolerability between 
the 2 preparations.22
Fixed combination  
of brinzolamide–timolol
A fixed combination of timolol plus a different topical car-
bonic anhydrase inhibitor (Azarga®, brinzolamide 1% plus 
timolol 0.5%) has recently been marketed worldwide except 
for the US. Initial studies have demonstrated equivalent 
safety and efficacy compared with the fixed combination of 
dorzolamide and timolol.23 Reports of improved comfort and 
tolerability with the brinzolamide–timolol fixed combination 
have been published24–26 but the some of the marketing claims 
have been disputed.27
Efficacy studies
The ocular hypotensive efficacy of dorzolamide–timolol fixed 
combination therapy has been compared to various single 
ocular hypotensive medications including monotherapy with 
either of its components (dorzolamide hydrochloride 2% or 
timolol maleate 0.5%),9,28 bimatoprost 0.03%,29,30 latano-
prost 0.005%,31–34 or travoprost 0.004%.31,34,35   Comparisons 
have also been made between fixed combination therapy 
with dorzolamide–timolol and various concomitant dual 
therapy options including concomitant therapy with its 
components (dorzolamide hydrochloride 2% plus timolol 
maleate 0.5%),11,36,37 brimonidine tartrate 0.2% plus 
timolol maleate 0.5%,38,39 or brimonidine tartrate 0.2% 
plus latanoprost 0.005%.40 Additionally, the dorzolamide–
timolol fixed combination therapy has been compared 
to other available fixed combination therapies including 
latanoprost–timolol,41–43 and brimonidine–timolol.44,45 The 
fixed combination dorzolamide–timolol therapy has also 
been studied retrospectively in patients who were being 
treated with dorzolamide–timolol but had previously not 
responded to prostaglandin analogs.46 Prophylactic treatment 
after phacoemulsification surgery was studied comparing 
dorzolamide–timolol fixed combination therapy with bri-
monidine tartrate 0.2% monotherapy and a control group of 
patients not receiving any ocular hypotensive medications.47 
Some fixed combination therapies of prostaglandins (latano-
prost or travoprost) with timolol maleate 0.5% are available 
outside the US but did not achieve FDA approval for use 
in the US because they did not meet the specific additional 
demonstrated efficacy targets above and beyond what can be 
accomplished with a prostaglandin.6
Comparisons with monotherapy  
of its components dorzolamide 
hydrochloride 2% or timolol  
maleate 0.5%
The IOP-lowering effect of the dorzolamide–timolol fixed 
combination has been found to be greater than that of 
either of its components when they are each administered 
as monotherapy.9,28 In a 3-month, parallel, randomized, 
  multicenter clinical trial comparing dorzolamide–timolol 
fixed combination therapy dosed twice daily with mono-
therapy with either dorzolamide hydrochloride 2% 3 times 
daily or timolol maleate 0.5% twice daily in patients who 
had washed out all ocular hypotensive medications, IOP Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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was measured at morning trough (hour 0) and peak (2 hours 
post-dose). IOP reduction was found to be greater in the fixed 
combination therapy group than in the dorzolamide or timolol 
groups. At morning trough (hour 0) of the 3-month visit, the 
mean IOP reduction from baseline was 27.4% (−7.7 mmHg) 
for the fixed combination therapy, 15.5% (−4.6 mmHg) for 
the dorzolamide group, and 22.2% (−6.4 mmHg) for the 
timolol group. At morning peak measurement (hour 2) of 
the 3-month visit, the mean IOP reduction from baseline 
was 32.7% (−9.0 mmHg), 19.8% (−5.4 mmHg), and 22.6% 
(−6.3 mmHg) for the fixed combination, dorzolamide, and 
timolol groups, respectively.9
The dorzolamide–timolol fixed combination therapy 
dosed twice daily was also compared with monotherapy 
with either dorzolamide hydrochloride 2% 3 times daily or 
timolol maleate 0.5% twice daily in patients whose IOP was 
not sufficiently controlled on timolol maleate 0.5% twice 
daily alone. In a parallel, randomized, 3-month, multicenter 
clinical trial, patients who were not responding well to timolol 
maleate 0.5% monotherapy were treated with a 3-week run-in 
of timolol maleate 0.5% twice daily and then randomized to 
receive either the dorzolamide–timolol fixed combination 
therapy twice daily, timolol maleate 0.5% monotherapy 
twice daily, or dorzolamide hydrochloride 2% monotherapy 
3 times daily. The dorzolamide–timolol fixed combination 
therapy was numerically better at all study time points 
providing additional IOP-lowering effect compared with 
its individual components and was statistically superior to 
its individual components at all time points except for month 
2, hour 0 versus timolol maleate 0.5% monotherapy and 
month 2, hour 2 compared with dorzolamide hydrochloride 
2% monotherapy.28
Comparisons with concomitant 
administration of its components 
dorzolamide hydrochloride 2% plus 
timolol maleate 0.5%
The efficacy of the dorzolamide–timolol fixed combination 
(dorzolamide–timolol dosed twice daily) was also found to 
be comparable to the IOP-lowering effect of its individual 
components when administered concomitantly (dorzolamide 
hydrochloride 2% 3 times daily plus timolol maleate 0.5% 
twice daily).11,36,37 A statistically significant additional IOP 
reduction was observed in 1study in which the dorzolamide–
timolol fixed combination therapy was used as a replacement 
therapy for patients who were being treated with both a beta 
blocker and dorzolamide.36
In a multicenter, randomized, parallel, 3-month clinical 
trial with a 1-year open label extension, the IOP-lowering 
effects of the dorzolamide–timolol fixed combination were 
found to be comparable to those of the concomitant admin-
istration of its components (dorzolamide hydrochloride 2% 
plus timolol maleate 0.5%) and these effects were main-
tained for up to 1 year. When compared with the baseline 
2-week timolol maleate 0.5% run-in treatment period, the 
dorzolamide–timolol fixed combination therapy reduced IOP 
by approximately 14% at hour 0 (just before the morning 
does), 20% at hour 2, and 15% at hour 8 during 3 months of 
treatment. At this same time point, the IOP-lowering effect 
of concomitant therapy with dorzolamide hydrochloride 2% 
and timolol maleate 0.5% was approximately 16%, 20%, 
and 17% at hours 0, 2, and 8, respectively. At hours 0, 2, and 
8, the authors found that there was .97% confidence that 
treatment with dorzolamide–timolol fixed combination was 
equivalent to concomitant administration of its components. 
During the 1 year open-label extension, the reductions in IOP 
seen at the 3-month timeframe were maintained, the mean 
IOP reduction ranging from 14% to 15% at hour 0 and from 
20% to 21% at hour 2.11
Comparison of the efficacy of the dorzolamide–timolol 
fixed combination therapy dosed twice daily with the con-
comitant administration of its components, dorzolamide 
hydrochloride 2% twice daily and timolol maleate 0.5% twice 
daily, was also studied in a randomized, parallel, multicenter, 
3-month clinical trial in patients who had been treated with a 
2-week run-in period of timolol maleate 0.5% monotherapy. 
These results showed that compared with the timolol maleate 
0.5% monotherapy baseline, additional IOP-lowering of 16% 
was observed at trough (hour 0) and 22% at peak (hour 2) 
at the 3-month timeframe in both the concomitant therapy 
and fixed combination therapy groups. These results were 
clinically and statistically equivalent, extremely small point 
differences (concomitant IOP minus fixed combination IOP) 
of 0.01 mmHg at trough (hour 0) and 0.08 mmHg at peak 
(hour 2) being observed in this study.37
A prospective, randomized, multicenter, parallel clinical 
trial and a prospective, nonrandomized comparative 
replacement study were both conducted by the same 
group of investigators.36 The results of the randomized, 
parallel study indicated that the dorzolamide–timolol fixed 
combination therapy was as effective as the concomitant 
administration of its components at lowering IOP. However, 
in the replacement comparative study, the fixed combination 
therapy showed a statistically significant additional 
reduction in IOP.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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In the randomized, parallel study patients were random-
ized to receive either dorzolamide–timolol fixed combination 
therapy or a topical carbonic anhydrase inhibitor (CAI) and 
nonselective beta blocker after a 1-month run-in period using 
the separate components and were treated on the randomized 
therapy for 1 month. Mean baseline IOPs were 18.4 mmHg 
(peak) and 21.0 mmHg (trough) in the dorzolamide–timolol 
group and 17.6 mmHg (peak) and 19.8 mmHg (trough) in the 
concomitant therapy group. The percentage change in IOP 
was −3.2% at peak and −6.5% at trough for the dorzolamide–
timolol fixed combination therapy group and −0.3% at peak 
and −3.2% at trough for the concomitant therapy group. 
These differences between peak and trough IOP values were 
not statistically significant.36
In the replacement therapy study, glaucoma patients who 
were using a nonselective beta blocker and dorzolamide 
hydrochloride 2% were changed to the fixed combination 
dorzolamide–timolol therapy for 1 month. Mean baseline 
IOP measured before switching to the replacement therapy 
with dorzolamide–timolol was 19.4 mmHg and after 4 weeks 
of treatment on the replacement therapy, a significant addi-
tional IOP reduction of −1.7 mmHg (−8.8%) was observed 
(P , 0.0001), 81% of eyes overall having equal or lower 
IOP on the fixed combination dorzolamide–timolol therapy 
compared with the concomitant therapy.36
Comparison with bimatoprost  
0.03% monotherapy
In a large multicenter study in patients whose IOP was 
uncontrolled with timolol maleate 0.5% monotherapy, the 
IOP-lowering effects of bimatoprost 0.03% monotherapy 
were more consistent and significantly greater than those 
of the fixed combination dorzolamide–timolol therapy.29 In 
a separate and smaller 3-center crossover study, the results 
indicated that the IOP-lowering effects of these 2 therapies 
were statistically similar in patients with glaucoma or OH 
who were randomized after a washout period.30
A 3-month, randomized, multicenter, parallel study 
was conducted to compare the dorzolamide–timolol fixed 
combination therapy dosed twice daily against bimatoprost 
0.03% monotherapy dosed once daily in patients with glau-
coma or OH who had IOP of $22 mmHg despite treatment 
with timolol maleate 0.5% monotherapy. All study subjects 
were washed out of any ocular hypotensive except for 
timolol maleate 0.5% and then treated with timolol maleate 
0.5% monotherapy for at least 2 weeks prior to the baseline 
study visit. At the 3-month timeframe bimatoprost 0.03% 
monotherapy lowered mean IOP by 6.8 mmHg whereas the 
dorzolamide–timolol fixed combination therapy lowered 
mean IOP by 5.0 mmHg (P , 0.001). Also, the percentage of 
patients achieving target IOP measurements of #13 mmHg 
through #16 mmHg in 1 mmHg increments at the 0800 hours 
data point for the 3 month visit were all statistically signifi-
cantly higher (all more than twice as high) for the bimatoprost 
monotherapy group compared with the dorzolamide–
timolol fixed combination therapy group. The percentage of 
patients achieving target IOP measurements of #17 mmHg 
through #20 mmHg in 1 mmHg increments at the same 
timeframe were all higher for the bimatoprost monotherapy 
group but were not statistically significantly higher than the 
dorzolamide–timolol fixed combination therapy group.29
A 3-center, randomized, crossover comparison study 
designed with a 4-week washout period followed by two 
8-week treatment periods was conducted, with diurnal IOP 
measurements taken at 0800, 1000, and 1600 hours. The diur-
nal untreated baseline IOP was 24.8 mmHg and on the last 
day of treatment the mean diurnal IOP was 17.4 mmHg for 
the bimatoprost monotherapy group and 18.1 mmHg for the 
dorzolamide–timolol fixed combination therapy group. These 
data showed that the individual time points for IOPs were not 
statistically different between the 2 treatment groups.30
Comparison with latanoprost  
0.005% monotherapy
Compared with latanoprost 0.005% monotherapy dosed once 
daily, the dorzolamide–timolol fixed combination dosed 
twice daily was found to be equally effective at lowering IOP 
in parallel studies32,33 enrolling patients with OAG or OH, 
more effective at IOP reduction in a parallel study34 enrolling 
patients with pseudoexfoliation glaucoma, and less effec-
tive as an ocular hypotensive regimen in a crossover study31 
enrolling patients with POAG whose OH was uncontrolled 
with beta blocker therapy.
Two parallel, randomized, 3-month multicenter clinical 
trials, one in the US and the other in Europe/Israel, were 
conducted in order to compare the dorzolamide–timolol 
fixed combination therapy dosed twice daily versus latano-
prost 0.005% monotherapy dosed once daily. Patients 
with OH or OAG were washed out of their usual ocular 
hypotensive medications and then those with a baseline 
IOP $ 24 mmHg in at least 1 eye were randomized to 
either the dorzolamide–timolol fixed combination group or 
the latanoprost   monotherapy group. The mean diurnal IOP 
(mean of   measurements made at 0800, 1000, 1400, and 
1600 hours) was used to assess efficacy. In the US study, the 
mean daytime diurnal IOP measurements were 26.1 mmHg Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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at baseline and 18.9 mmHg at 3 months in the dorzolamide–
timolol fixed combination group versus 25.6 mmHg at base-
line and 18.4 mmHg at 3 months in the latanoprost group. In 
the Europe/Israel study, the mean diurnal IOP measurements 
were 25.3 mmHg at baseline and 17.4 mmHg at 3 months 
in the dorzolamide–timolol fixed combination group versus 
24.7 mmHg at baseline and 17.5 mmHg at 3 months in the 
latanoprost monotherapy group. At the 3-month timeframe 
the difference between treatments in mean IOP change 
was −0.04 mmHg (95% confidence interval [CI] −0.85, 
0.77 mmHg) in the US study and −0.57 mmHg (95% 
CI −1.31, 0.16 mmHg) in the Europe/Israel study, showing 
that the dorzolamide–timolol fixed combination therapy was 
equally effective at lowering IOP as the latanoprost 0.005% 
therapy.32
A randomized, prospective, crossover study was con-
ducted at 2 centers enrolling patients with POAG or OH 
who had undergone a 6-week washout period and were then 
randomized to be treated with dorzolamide–timolol fixed 
combination therapy and latanoprost 0.005% monotherapy in 
a crossover study. Patients first received 6 months of treatment 
with either dorzolamide–timolol fixed combination therapy 
dosed twice daily or latanoprost 0.005% monotherapy dosed 
once daily. Both of these therapies demonstrated clinically 
similar 24-hour IOP-lowering efficacies. After 6 months of 
treatment with the randomized therapy, patients were then 
crossed over to the other therapy for an additional 6 months 
without a washout period separating the 2 treatments. The 
mean 24-hour IOP was reported after 2 and 6 months of cross-
over treatment. After 6 months of treatment, 24-hour IOPs 
were 18.1 mmHg for the dorzolamide–timolol group and 18.3 
for the latanoprost group. Compared with 2 months of therapy 
the dorzolamide–timolol group did not show a significant 
change in mean 24-hour IOP but the latanoprost group did 
show an additional reduction of 0.3 mmHg (P = 0.01).33
Comparison with travoprost  
0.004% monotherapy
The IOP-lowering effects of dorzolamide–timolol fixed 
combination therapy were shown to be both better34 and 
worse31,35 than the efficacy of travoprost 0.004% monotherapy 
in 3 small, single-center studies.
A randomized, parallel, 6-week, single-center study in 
patients with OAG or OH found that fixed combination 
therapy with dorzolamide–timolol dosed twice daily was 
less efficacious than monotherapy with travoprost 0.004% 
dosed once daily. IOP reduction and percentage of IOP 
reduction were compared for measurements made at 0800, 
1200, 1600, and 2000 hours. Mean average IOP reductions 
from baseline were −7.5 mmHg and −7.1 mmHg at 3 and 
6 weeks, respectively, for the travoprost monotherapy 
group and −4.8 mmHg and −4.5 mmHg at 3 and 6 weeks, 
respectively, for the dorzolamide–timolol fixed combination 
therapy group. The better mean diurnal IOP reduction seen 
in the patients receiving the travoprost 0.004% monotherapy 
compared with those patients receiving the dorzolamide–
timolol fixed combination therapy was statistically significant 
at both follow-up time points (P , 0.01).35
Comparison with either latanoprost 
0.005% monotherapy or travoprost 
0.004% monotherapy in the same trial
Two studies mentioned previously are summarized separately 
in this section because they were designed to compare fixed 
combination dorzolamide–timolol therapy with either latano-
prost 0.005% monotherapy or travoprost 0.004% monother-
apy in the same clinical trial.31,34 The IOP-lowering effects 
of fixed combination dorzolamide–timolol therapy were 
found to be better than both of the prostaglandin derivatives 
in patients with pseudoexfoliation glaucoma in one study34 
but worse than the prostaglandin derivatives in patients with 
POAG and OH in another study.31
The first of these studies was a randomized, prospective 
trial in which 50 patients with pseudoexfoliation glaucoma 
were randomized to receive 6 months of either dorzolamide–
timolol fixed combination therapy or monotherapy with either 
latanoprost 0.005% or travoprost 0.004%. All treatments 
considerably reduced the IOP in these patients throughout 
the 6 months. In the latanoprost group the mean IOP reduc-
tion at the 6-month timeframe was −8.2 mmHg, compared 
with a mean IOP reduction of −9.3 mmHg in the travoprost 
group and a mean IOP reduction of −11.5 mmHg in the 
dorzolamide–timolol group. A comparison of these groups 
showed that dorzolamide–timolol fixed combination therapy 
was more effective than either latanoprost 0.005% or travo-
prost 0.004% monotherapy in lowering IOP (P , 0.05) in 
these patients with pseudoexfoliation glaucoma and that there 
was no difference between the prostaglandin derivatives.34
The second trial was a prospective, randomized, crossover, 
single-center study in patients having POAG and OH not con-
trolled with beta blocker therapy. Patients received sequential 
3-month courses of monotherapy with latanoprost 0.005%, 
monotherapy with travoprost 0.004%, or fixed combination 
therapy with dorzolamide–timolol for the initial therapy. 
During the crossover period, the selection of the treatment 
was randomized. The fixed combination dorzolamide–timolol Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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was less effective in reducng IOP (−14.3% reduction) than 
the latanoprost 0.005% monotherapy (−22.1% reduction) or 
the travoprost 0.004% monotherapy (−18.4% reduction). The 
IOP-lowering effects were comparable for the 2 prostaglandin 
derivatives and superior to the effect of the dorzolamide–
timolol fixed combination therapy. A selection bias against 
timolol maleate 0.5% weakened this study, as patients were 
enrolled who were already known to respond inadequately 
to beta blocker therapy prior to study enrollment.31
Comparison with concomitant 
administration of brimonidine tartrate 
0.2% plus timolol maleate 0.5%
The efficacy of the dorzolamide–timolol fixed combination 
therapy and the concomitant administration of brimonidine 
tartrate 0.2% plus timolol maleate 0.5% were found to be 
comparable.38,39 A 6-month, randomized, parallel, multicenter 
clinical trial was conducted in order to compare the efficacy 
of the fixed combination dorzolamide–timolol dosed twice 
daily with concomitant administration of brimonidine tartrate 
0.2% plus timolol maleate 0.5% each dosed twice daily in 
patients with glaucoma or OH after an open-label 3-week 
timolol maleate 0.5% monotherapy run-in period. At the 
3-month timeframe, hour 0, the dorzolamide–timolol group 
had a change in IOP of −3.66 mmHg versus −4.15 mmHg 
for the brimonidine plus timolol group, with a statistically 
significant treatment difference of 0.49 mmHg. At month 3, 
hour 2, the dorzolamide–timolol group had an adjusted mean 
change in IOP of −5.04 mmHg compared with −5.41 mmHg 
for the brimonidine plus timolol group, with a statistically 
comparable treatment difference of 0.36 mmHg. At all 
other timeframes the 2 treatment groups were statistically 
comparable, the 95% CIs of the treatment differences being 
within ±1.5 mmHg.38
In another study, the IOP-lowering effects of dorzolamide–
timolol fixed combination therapy dosed twice daily was 
found to be comparable to concomitant administration of 
brimonidine tartrate 0.2% plus timolol maleate 0.5% dosed 
twice daily at 3 of the 4 time points measured.39 A 3-month 
randomized, parallel, multicenter clinical trial was conducted 
enrolling patients with POAG, pseudoexfoliative glaucoma, 
or pigmentary glaucoma who were randomized to the 2 treat-
ment groups after a 3-week run-in period of timolol maleate 
0.5% monotherapy if their peak IOP was $22 mmHg. At the 
month 3 trough (hour 0) and at both month 1 time points, 
the 95% CIs of the treatment differences were within the 
prespecified statistical boundary of ±1.5 mmHg. However, 
at the month 3, hour 2 time point, the 2 treatments were 
not comparable. The brimonidine plus timolol group had a 
slightly higher mean reduction in IOP (−5.27 mmHg) over the 
dorzolamide–timolol treatment group (−4.30 mmHg) with 
a treatment difference of 0.97 mmHg and a 95% CI whose 
upper limit was beyond the ±1.5 mmHg used to demonstrate 
statistical comparability.39
Comparison with concomitant 
administration of brimonidine tartrate 
0.2% plus latanoprost 0.005%
The concomitant administration of brimonidine tartrate 0.2% 
plus latanoprost 0.005% was found to provide superior IOP 
control in patients with glaucoma and OH compared with 
the dorzolamide–timolol fixed combination therapy in 2 
randomized, parallel, multicenter clinical studies, one last-
ing 12 weeks and the other 3 months. The mean IOP reduc-
tion at each visit was significantly greater in the patients 
treated with the brimonidine tartrate 0.2% plus latanoprost 
0.005% concomitant therapy at each follow-up visit in both 
clinical trials. In the first study, the mean IOP reduction at 
peak drug effect at the 6-week visit was −9.2 mmHg for the 
brimonidine plus latanoprost group and −6.7 mmHg for the 
dorzolamide–timolol group (P = 0.024). At the 12-week 
visit, IOP reductions were −9.0 mmHg and −6.5 mmHg for 
the brimonidine plus latanoprost and dorzolamide–timolol 
groups, respectively (P = 0.044). In the second study, at the 
1-month visit, the mean IOP reduction was −10.6 mmHg for 
the brimonidine plus latanoprost group and −6.3 mmHg for 
the dorzolamide-timolol group (P = 0.001). At the 3-month 
visit, IOP reductions were −9.1 mmHg and −6.6 mmHg for 
the brimonidine plus latanoprost group and the dorzolamide–
timolol group, respectively (P = 0.047).40
Comparison with fixed combination 
therapy with latanoprost  
0.005%–timolol maleate 0.5%
Fixed combination therapy with latanoprost–timolol was 
found to be slightly more effective than the dorzolamide–
timolol fixed combination therapy in reducing mean diurnal 
IOP in one study involving patients with POAG or OH that 
were not well controlled on monotherapy.43 In a crossover 
study involving patients with POAG or pigment dispersion 
glaucoma, or OH that had been treated with a run-in period 
of timolol maleate 0.5%, fixed combination therapy with 
latanoprost–timolol was found to be not statistically different Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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from the dorzolamide–timolol fixed combination therapy.42 
In another crossover single-center study involving patients 
with POAG or OH who had been treated with a run-in 
period of timolol maleate 0.5%, the dorzolamide–timolol 
and latanoprost–timolol fixed combination therapies were 
found to be statistically similar.41
Patients with elevated IOP due to POAG or OH whose 
IOP was insufficiently responsive to monotherapy, defined as 
those patients whose IOP remained .20 mmHg on 1 ocular 
hypotensive medication, were enrolled in a 3-month, random-
ized, parallel, multicenter clinical study comparing 2 fixed 
combination therapies, dorzolamide–timolol dosed twice 
daily or latanoprost–timolol dosed once daily. Patients were 
randomized at the baseline visit, which was scheduled after 
a washout period that varied depending on the drug class 
of the monotherapy that was used before enrollment. Mean 
diurnal IOPs were similar at baseline and mean reductions 
in IOP were −9.4 mmHg in the latanoprost–timolol group 
and −8.4 mmHg in the dorzolamide–timolol group at the 
3-month timeframe. The mean difference in IOP reduction 
between the 2 treatment groups was 1.0 mmHg, a 95% CI of 
0.31 to 1.69 (P = 0.005) showing statistically significantly 
more favorable results in the latanoprost–timolol group.43
A randomized, crossover comparison study was con-
ducted at 2 centers to compare the efficacy of dorzolamide–
timolol fixed combination therapy dosed twice daily versus 
the fixed combination of latanoprost–timolol dosed once 
daily. Patients enrolled in this study had POAG or OH and 
were started on a 4-week run-in period of timolol maleate 
0.5% monotherapy. Then they were randomized to receive 
1 of the 2 fixed combination therapies being studied for an 
8-week period. Timolol maleate 0.5% monotherapy was 
used for another for an 8-week period, and then the groups 
were treated with the other fixed combination therapy for an 
8-week period (the crossover therapy period). The diurnal IOP 
was measured every 2 hours from 0800 to 2000 hours and 
statistical analysis was performed on the 8-week data. The 
mean diurnal IOP was 17.3 mmHg for latanoprost–timolol 
and 17.0 mmHg for dorzolamide–timolol, showing no statis-
tical difference (P = 0.36) between the 2 fixed combination 
therapies.42
A prospective, randomized, single-center, crossover 
clinical study was conducted in patients with POAG or OH 
who had been treated with a 6-week run-in period of timolol 
maleate 0.5% monotherapy. After the run-in period patients 
were randomized to receive dorzolamide–timolol dosed twice 
daily or latanoprost–timolol dosed once daily plus a placebo 
of artificial tears for the second daily dose. Patients were 
treated with the randomized fixed combination therapy for 
6 weeks then were switched to the other fixed combination 
therapy (the crossover therapy period) for another 6 weeks 
without the use of a washout period. The mean diurnal 
IOP was 19.5 mmHg for the dorzolamide–timolol group 
and 18.9 mmHg for the latanoprost–timolol group with no 
significant difference found between these treatments at any 
time point.41
A prospective, randomized, single-masked, multicenter 
study of patients with POAG and OH who did not respond 
sufficiently to beta blocker therapy alone demonstrated 
noninferiority of either fixed combinations of dorzolamide–
timolol or latanoprost–timolol after 4 and 12 weeks of treat-
ment. They did find, however, that a higher percentage of 
patients treated with the latanoprost–timolol combination 
achieved IOP # 16 mmHg.48
Comparison with fixed combination 
therapy with travoprost  
0.004%–timolol maleate 0.5%
A prospective, multicenter, double-masked trial random-
ized 319 patients to receive a fixed combination of either 
travoprost–timolol once daily in the morning or dorzolamide–
timolol twice daily. The travoprost–timolol group had a 
significantly lower mean diurnal IOP than the dorzolamide–
timolol group (16.5 mmHg ± 0.23 vs 17.3 mmHg ± 0.23; 
P = 0.011). Additionally, the travoprost–timolol combination 
achieved greater mean IOP reductions from baseline (35.3% 
to 38.5%) than dorzolamide–timolol (32.5% to 34.5%).49
Comparison with fixed combination 
therapy with brimonidine tartrate  
0.2%–timolol maleate 0.5%
In 2 large multicenter clinical studies, the efficacy of 
dorzolamide–timolol fixed combination therapy was found to 
be both worse45 than and comparable44,45 to the IOP-lowering 
effect of fixed combination therapy with brimonidine–timolol 
in patients with POAG or OH. The efficacy of fixed combi-
nations of either dorzolamide–timolol dosed twice daily or 
brimonidine–timolol dosed twice daily was evaluated when 
used as monotherapy or as adjunctive therapy to a prosta-
glandin analog in patients with POAG or OH in a random-
ized, 3-month, parallel, multicenter clinical trial. Fixed 
combination therapy with dorzolamide–timolol provided 
the same IOP-lowering effect as brimonidine–timolol fixed Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  combination therapy when these were used as   adjunctive 
therapy to a prostaglandin analog (eg, bimatoprost, latano-
prost, or travoprost) in one study enrolling patients with 
POAG or OH. In this study the patients who were not on a 
prostaglandin analog had a statistically significantly worse 
IOP-lowering effect from dorzolamide–timolol than from 
brimonidine–timolol when either of these fixed combina-
tion therapies was used as the only ocular hypotensive. 
At the 3-month timeframe, the mean reduction from baseline 
IOP for patients who were not on a prostaglandin analog 
was −6.7 mmHg for dorzolamide–timolol monotherapy 
compared with −7.7 for brimonidine–timolol monotherapy 
(P = 0.040). The mean reduction from baseline of patients 
for whom the fixed combination therapy was an adjunct 
to a prostaglandin analog was −5.2 mmHg for patients on 
dorzolamide–timolol therapy compared with −6.9 mmHg for 
patients on brimonidine–timolol therapy (P = 0.213).45
In a separate prospective, randomized, crossover com-
parison, multicenter clinical study, the efficacy of fixed 
combination therapy with dorzolamide–timolol dosed twice 
daily was similar to that of brimonidine–timolol dosed twice 
daily in patients with POAG or OH. Patients were random-
ized at the baseline visit which was scheduled after a wash-
out period that varied depending on the drug class of the 
monotherapy used before enrollment. After the appropriate 
washout period, patients were randomized to receive either 
dorzolamide–timolol or brimonidine–timolol for 4 weeks, 
then the patients underwent a 4-week washout period before 
they were started on the other fixed combination therapy for 
another 4 weeks (the crossover therapy period), with IOP 
measured at 0800, 1200, and 1600 hours. The mean diurnal 
IOP at baseline for all patients was 22.9 mmHg and both 
fixed combination therapies significantly reduced the mean 
diurnal IOP. The mean diurnal IOP at the 4-week timeframe 
was 15.0 mmHg (−7.8 mmHg mean IOP reduction) for the 
brimonidine–timolol therapy and 15.4 mmHg (−7.4 mmHg 
mean IOP reduction) for the dorzolamide–timolol therapy 
(P = 0.510 for mean diurnal IOP and P = 0.430 for mean 
IOP reduction).44
Other efficacy studies
The IOP-lowering effect of dorzolamide–timolol fixed com-
bination therapy was studied retrospectively in a population 
of glaucoma patients who had not responded to prostaglandin 
analog therapy and was found to significantly reduce the 
IOP in this patient population whose major diagnosis was 
  pseudoexfoliation glaucoma (58% of patients in the study). 
A retrospective medical record review identified glaucoma 
patients who were nonresponders to prostaglandin analogs, 
defined as those having an IOP-lowering effect less than 
15% compared with their baseline IOP measurements, and 
had subsequently been dosed with dorzolamide–timolol 
fixed combination therapy. Twelve-hour diurnal curves were 
prepared for each of the therapy regimens from the available 
medical records of the chosen patients. The authors found that 
the dorzolamide–timolol fixed combination therapy signifi-
cantly reduced IOP in patients overall, from 25.4 mmHg down 
to 20.2 mmHg (P , 0.0001). Dorzolamide–timolol was also 
found to reduce the mean IOP fluctuations over the 12 hours 
from 8.6 mmHg down to 4.3 mmHg (P , 0.0001).46
Prophylactic treatment with dorzolamide–timolol fixed 
combination therapy was more effective than brimonidine 
tartrate 0.2% monotherapy in reducing the IOP in patients 
undergoing phacoemulsification cataract surgery. In this 
prospective, randomized, single-center study patients 
were randomly assigned to 3 treatment groups: 1 drop of 
dorzolamide–timolol, 1 drop of brimonidine tartrate 0.2%, or 
no ocular hypotensive treatment (control group). The IOP was 
measured at 6 hours and 24 hours after surgery. At both time 
points the IOPs after surgery were lower in the dorzolamide–
timolol treatment group. Six hours after surgery, the mean 
IOP was 16.3 mmHg in the dorzolamide–timolol group, 
20.6 mmHg in the brimonidine group, and 24.6 mmHg in 
the control group. At 24 hours after surgery, the mean IOP 
was found to be higher in the control group (19.8 mmHg) 
than in the dorzolamide–timolol group (14.1 mmHg) and the 
brimonidine group (17.5 mmHg).47
A prospective, 4-week trial in patients who demonstrated 
at least 15% IOP reduction following a minimum of 15 days’ 
therapy with latanoprost and whose IOP was still considered 
higher than the clinically determined target level random-
ized 1 eye to additive treatment with fixed combination 
dorzolamide–timolol. The fellow was used as a monotherapy 
control. Starting from similar baselines, mean diurnal IOP 
levels in the add-on group were 7.4% lower than those of the 
monotherapy group (P = 0.01).50
An open-label, 12-week Canadian study evaluated 
patients previously untreated for OAG or OH. All patients 
were initially treated with fixed combination dorzolamide–
timolol. If a target of 5 mmHg or at least 20% IOP reduction 
from baseline was not met by 6 weeks, additional therapy 
with latanoprost was begun. Of 164 enrolled patients, 
28 (17.1%) were changed to combination therapy with 
dorzolamide–timolol and latanoprost. Between weeks 6 and 
12, the dorzolamide–timolol alone group maintained IOP 
control within the target range, and the group with the added Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  prostaglandin experienced additional 6.3 mmHg (22%) IOP 
lowering. At the completion of the study, the dorzolamide–
timolol arm had a 12.2 mmHg (40.4%) decrease from 
baseline IOP, whereas the dorzolamide–timolol plus latano-
prost group was 13.4 mmHg (39.7%) lower than baseline.51 
  Therefore, if a 20% IOP reduction cannot be achieved 
with first-line dorzolamide “monotherapy”, addition of a 
prostaglandin is likely to bring the IOP within below the 
target level.
Safety and tolerability
Overview of safety data
The use of dorzolamide–timolol fixed combination therapy has 
been shown to be well tolerated by patients, and the adverse 
event profile mirrors those of its individual   components. 
No additional tolerability issues have been identified that are 
specific to this fixed combination formulation.18,52 The toler-
ability of dorzolamide–timolol fixed combination therapy 
was shown to be comparable to that of timolol maleate 
0.5%, latanoprost 0.005%, and the fixed combination of 
latanoprost–timolol in a large (3481 patients) multicenter 
clinical study conducted at 9 centers in The Netherlands 
where these 4 glaucoma medications were the most frequently 
prescribed therapies. Most patients (79%) in this study were 
satisfied with their glaucoma medications and only 9% of 
patients discontinued their eye drops due to adverse events 
or side effects.53
Ocular and local adverse events
Burning and stinging
The most common adverse events typically reported by up 
to 30% of patients are ocular and local effects including mild 
to moderate transient burning or stinging sensation, which is 
likely due to the dorzolamide hydrochloride 2% component, 
and dysgeusia (taste perversion reported as bitter, sour, or 
unusual taste).18,52 These data are noted in the manufacturer’s 
product labeling which includes results from their original 
clinical studies and has also been reproduced in other large 
comparative trials where the incidences of drug-related 
ocular burning or stinging sensation with dorzolamide–
timolol were higher than those with other ocular hypotensive 
medications.18 In these large comparative studies, other 
adverse events were reported, some of incidence rates being 
statistically significantly different between the dorzolamide–
timolol fixed combination therapy and the comparator 
therapy. Ocular burning and stinging was more frequent 
with dorzolamide–timolol than with brimonidine–timolol 
fixed combination in 2 studies (P = 0.02744 and P , 0.00145), 
concomitant administration of brimonidine tartrate 0.2% 
plus timolol maleate 0.5% (P , 0.001),38 timolol maleate 
0.5% in 2 studies (P = 0.0089 and P , 0.00128), bimatoprost 
0.03% (P = 0.0005),30 or latanoprost 0.005% in 2 studies 
(P , 0.00133 and P , 0.0532).
eye pain
When comparing dorzolamide–timolol against latanoprost–
timolol, transient eye pain that occurred after drug admin-
istration and was not long lasting was reported significantly 
more often (P = 0.034) with dorzolamide–timolol recipients 
(11.7% of patients) than with latanoprost–timolol recipients 
(4.0% of patients).43 Eye pain was also statistically sig-
nificantly less in the dorzolamide–timolol therapy group 
compared with concomitant treatment with its components 
(dorzolamide hydrochloride 2% plus timolol maleate 0.5%) 
in one study (299 patients, P = 0.014)37; however, eyelid pain 
or discomfort was statistically significantly greater in the 
dorzolamide–timolol group in another study (242 patients, 
P = 0.036).11
Corneal signs
All corneal signs (P = 0.011) and specifically superficial 
punctate keratitis (P = 0.005) were statistically significantly 
lower in the dorzolamide–timolol fixed combination therapy 
compared with concomitant therapy with its components 
(dorzolamide hydrochloride 2% plus timolol maleate 
0.5%).37 In vitro study of the effects of dorzolamide 
2%–timolol 0.5% fixed combination and brimonidine 
0.2%–timolol 0.5% fixed combination on tissue culture 
plates with human conjunctival and corneal epithelial cells 
demonstrated a significant reduction in live cells exposed 
to dorzolamide–timolol compared with brimonidine–timolol 
for both the conjunctival and corneal tissue cultures.54 These 
findings may be relevant for patients receiving chronic 
therapy for glaucoma.
Conjunctivitis
Conjunctival hyperemia was reported significantly less often 
by patients treated with dorzolamide–timolol than those 
receiving either latanoprost 0.005% or travoprost 0.004% 
monotherapy in 2 studies,31,34 latanoprost–timolol fixed 
combination therapy (P = 0.045),42 or bimatoprost 0.03% 
in 2 studies (P = 0.00929 and P = 0.01330) and was lower 
but not statistically significantly less frequent compared 
to brimonidine–timolol fixed combination therapy in one 
study.44 Conjunctivitis was reported significantly less often 
in the dorzolamide–timolol group than in the dorzolamide Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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monotherapy group (P = 0.034).28 The side effects of 
conjunctival hyperemia were also more frequent in another 
study after latanoprost 0.005% and travoprost 0.004% therapy 
than after the dorzolamide–timolol therapy.31
Other effects
Blurry vision was significantly higher with fixed com-
bination dorzolamide–timolol therapy than with timolol 
maleate 0.5% in one study (P = 0.023).9 The tolerability 
profile of dorzolamide–timolol was similar to travoprost 
0.004% monotherapy,35 concomitant administration of 
brimonidine tartrate 0.2% plus timolol maleate 0.5%,28 and 
brimonidine tartrate 0.2% plus latanoprost 0.005% when 
dosed concomitantly in another study.18,40 In one study, 
hypertrichosis (P = 0.02) and ocular itching (P = 0.004) was 
reported more frequently with latanoprost 0.005% than with 
  dorzolamide–timolol.33 Overall comfort was   statistically sig-
nificantly higher with brimonidine–timolol fixed combination 
therapy than with dorzolamide–timolol fixed combination 
therapy (P = 0.014).45
Disturbances of taste
Bitter taste, dysgeusia, or taste perversion were the 
most commonly reported nonocular symptoms with the 
  dorzolamide–timolol fixed combination. They had a sta-
tistically significantly greater incidence than bimatoprost 
0.03% monotherapy (P = 0.027),29 travoprost 0.004% mono-
therapy (P = 0.0022),35 timolol maleate 0.5% monotherapy in 
2   studies (P = 0.0199 and P , 0.02028), latanoprost–timolol 
fixed combination therapy (P = 0.04),42 brimonidine–timolol 
fixed combination therapy (P , 0.001),45 concomitant 
therapy with brimonidine tartrate 0.2% plus timolol maleate 
0.5% in 2 studies (P , 0.00138 and P , 0.00139), and 
latanoprost 0.005% monotherapy in 2 studies (P , 0.000233 
and P , 0.0532). There were no statistically significant dif-
ferences for this nonocular symptom compared with the 
dorzolamide–timolol fixed combination therapy with con-
comitant administration of brimonidine tartrate 0.2% plus 
timolol maleate 0.5%39, monotherapy with either of its com-
ponents   (dorzolamide hydrochloride 2% or timolol maleate 
0.5%),28 or compared with concomitant   administration of its 
  components in 2 studies.11,37
Systemic adverse events
Systemic adverse events associated with CAIs include head-
ache, nausea, and urolithiasis, likely due to the   dorzolamide 
hydrochloride 2% component, as well as bradycardia, 
cardiac failure, heart block, hypotension, and respiratory 
symptoms or failure, likely due to the timolol maleate 
0.5%   component. Although serious, these events have been 
reported   infrequently during the marketing approval clinical 
trials and the postmarketing experience.18,52
Some of the clinical studies conducted on dorzolamide–
timolol fixed combination therapy beyond the marketing 
approval trials also had reports of systemic adverse events 
including: allergic reaction (0.7%38 and 1.1%45); benign 
atrial myxoma (0.7%);38 crystalluria (0.5%);11 dizziness 
(1.0%);28 dry mouth (2%);11 dyspnea (0.4%);39 eye dis-
charge (2%);11 foreign body sensation (2%);11 headache 
(1.1%,45 1.6%,43 and 3%11); fatigue (1.1%);45 flu (3.1%);41 
hyperglycemia (2%);11 lens opacity (5%);11 leukocytosis 
(3%);11 nausea (1.0%);28 oxaluria (0.5%);11 parathyroid 
hyperplasia (0.7%);38 pneumonia (0.7%);38 traumatic 
amputation of finger and thumb (0.7%);38 tremor (1.0%);28 
upper respiratory infection (6%);11 and urolithiais (2.5%).11 
In one comparative study, headache was reported more fre-
quently in the latanoprost group than in the dorzolamide–
timolol group (P = 0.04).33 A recent case of disseminated 
skin eruption and severe thrombocytopenia was attributed 
to treatment with dorzolamide–timolol. The skin rash 
resolved after stopping the eye drop, but reactivated fol-
lowing challenge with dapsone, suggesting sulphonamide 
cross-reactivity.55
Complete safety profile  
from marketing approval studies
The safety of fixed combination dorzolamide–timolol 
therapy was evaluated in 1035 patients with elevated IOP 
treated for POAG or OH as part of the clinical studies 
required to obtain approval from the FDA to market this 
ocular hypotensive.52 In these studies, approximately 5% 
of all patients discontinued therapy because of adverse 
reactions, dysgeusia or ocular burning or stinging being 
the most frequently reported adverse events (reported in 
up to 30% of patients). Adverse events that were reported 
in 5% to 15% of patients include conjunctival hyperemia, 
blurred vision, superficial punctate keratitis, and eye itching. 
Additional adverse events were reported in 1% to 5% of 
patients, including abdominal pain, back pain, blepharitis, 
bronchitis, cloudy vision, conjunctival discharge, conjunc-
tival edema, conjunctival follicles, conjunctival injection, 
conjunctivitis, corneal erosion, corneal staining, cortical 
lens opacity, cough, dizziness, dryness of eyes, dyspepsia, 
eye debris, eye discharge, eye pain, eye tearing, eyelid 
edema, eyelid erythema, eyelid exudate/scales, eyelid 
pain or discomfort, foreign body sensation, glaucomatous Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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cupping, headache, hypertension, influenza, lens nucleus 
coloration, lens opacity, nausea, nuclear lens opacity, 
  pharyngitis, postsubcapsular cataract, sinusitis, upper 
respiratory infection, urinary tract infection, visual field 
defect, and vitreous detachment.
The following adverse events occurred either at low inci-
dence (,1%) during the clinical trials or have been reported 
to the manufacturer during the use of dorzolamide–timolol 
in clinical practice, where these events were reported vol-
untarily from a population of unknown size and frequency 
of occurrence cannot be determined precisely by the manu-
facturer. The manufacturer includes them in their product 
labeling because of their seriousness, frequency, possible 
causal connection to dorzolamide–timolol fixed combina-
tion therapy, or a combination of these factors: bradycar-
dia,   cardiac failure, cerebral vascular accident, chest pain, 
  choroidal detachment following filtration surgery, depres-
sion, diarrhea, dry mouth, dyspnea, heart block, hypoten-
sion, iridocyclitis, myocardial infarction, nasal congestion, 
paresthesia,   photophobia,   respiratory failure, skin rashes, 
urolithiasis, and vomiting.52
Patient-focused perspectives
The goal of treatment for patients with glaucoma or OH 
is to control their IOP down to a level that preserves optic 
nerve function and stability of their visual fields. This is best 
achieved if the medication is harmonious with the patient’s 
lifestyle.28 As has been discussed previously, patient compli-
ance can affect medication efficacy. Using a fixed combina-
tion therapy can enhance patient adherence by simplifying 
the treatment regimen, improve drug delivery by reducing 
the washout effect, and limit toxicity by decreasing the 
  preservative burden.
Patient acceptance of medication includes tolerability 
of the side effects. Fixed combination dorzolamide–timolol 
carries the potential side effects of both of its component 
agents. Use may be contraindicated in patients with known 
cardiovascular disease or chronic obstructive pulmonary dis-
ease, and patients need to be counseled on potential adverse 
effects due to the timolol component’s beta-adrenergic block-
ing mechanism of action. The dorzolamide component is a 
sulfonamide agent, and its use is limited in the population 
of patients who have a known sensitivity to this class of 
drugs. In the preapproval FDA trials, approximately 5% of 
patients discontinued therapy because of intolerance/adverse 
  reactions. Dysgeusia and ocular burning or stinging were 
the most frequently reported adverse events (reported in 
up to 30% of patients), and 5% to 15% of patients reported 
conjunctival hyperemia, blurred vision, superficial punctate 
keratitis, or eye itching.52 When the fixed combination 
dorzolamide–timolol was compared with monotherapy with 
its 2 components in a 3-month, parallel, randomized clinical 
study, patients in the dorzolamide monotherapy treatment 
group and patients in the fixed combination dorzolamide–
timolol treatment group both reported a statistically sig-
nificantly higher rate of burning and stinging sensation 
(dorzolamide–timolol = 18%, dorzolamide monother-
apy = 14%) and taste perversion   (dorzolamide–timolol = 8%, 
dorzolamide monotherapy = 10%) than patients in the timolol 
(burning/stinging = 6%, P = 0.008 vs dorzolamide–timolol, 
taste   perversion = 1%, P = 0.019 vs dorzolamide–timolol) 
monotherapy treatment group, implicating dorzolamide 
as the likely offending agent. In this study a significantly 
greater proportion of patients in the dorzolamide–timolol 
treatment group discontinued from the study because of 
adverse effects compared with the timolol treatment group 
(7% vs 1%, P = 0.035).9
When 2 topical ocular medications are administered 
simultaneously or in close time proximity, the concentra-
tion of each is diluted and the excess medication is flushed 
away through the lacrimal system or down the cheek. This 
so-called “washout” is reduced by the use of fixed combina-
tion formulations which permit both medicines to be instilled 
in 1 drop with consistent drug concentrations. The reduced 
number of drops that a patient has to instill also reduces the 
burden of potentially toxic preservatives to which the eye 
is exposed.56
Conclusions
The efficacy of the fixed combination dorzolamide–timolol 
has been shown in controlled clinical studies to be greater 
than when either of its components is used individually 
as monotherapy, and it is also comparable to the use of 
its components concomitantly. Numerous clinical studies 
show comparable efficacy between the fixed combination 
dorzolamide–timolol and other topical agents used alone 
or in combination therapies. The safety profile of the fixed 
combination dorzolamide–timolol is similar to that of its 
individual components, and no additional tolerability issues 
have been identified specifically with this fixed combination 
therapy.
Patient compliance with their medication regimen 
is inversely related to the prescribed number of doses 
per day, and it is well documented that less frequent dos-
ing regimens result in better compliance across a variety of 
therapeutic classes. The convenience of a fixed combination Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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therapy has been shown to increase patient compliance in 
various studies. The fixed combination dorzolamide–timolol 
therapy improves patient compliance by reducing the 
  prescribed   number of doses per day. Use of fixed combination 
  dorzolamide–timolol also decreases the load of preserva-
tives to which the patients’ eyes are exposed and eliminates 
the effects of having the first instilled drug being diluted or 
“washed out” by the second instilled drug.
Rising health care costs are a concern for all, and the 
cost of treating glaucoma constitutes a significant financial 
load on the health care system. A cost analysis in the US has 
shown that generic nonselective beta blockers are the most 
inexpensive class of glaucoma medications, with generic 
timolol costing US$150.81 per year.57 The concomitant use of 
a CAI added US$385.41 per year. Thus concomitant therapy 
with the 2 components had a combined cost of US$536.22 
per year. This cost analysis used the brand name version of the 
fixed combination dorzolamide–timolol therapy (US$697.42 
per year) to calculate the costs because the generic version 
was not available at the time of the study.57 The generic 
version of the fixed combination dorzolamide–timolol is 
expected to reduce the yearly costs to patients and the health 
care system.
Thus, the role of fixed combination dorzolamide–timolol 
can be either as a replacement or adjunct therapy when a 
patient’s IOP is not adequately lowered with either of these 
2 medications individually. A limitation to the first-line use 
of fixed combination dorzolamide–timolol is that in the 
case of an adverse event or a side effect, identification of 
the offending component may be difficult. In some cases 
the fixed combination would need to be discontinued and 
the individual components administered independently to 
decipher which agent is to blame. Clinicians are advised 
to use their best medical judgment in choosing treatment 
options for their patients, taking into account that an indi-
vidual patient’s results may not exactly mimic the overall 
patient population results of any particular clinical study 
presented herein.
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